Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

iDose TR

Phase 3Small molecule

GGlaukos Corporation

iDose TR is one of 84 small molecule programs targeting Cataract. It is currently in Phase 3.

2

Indications

2

Total Trials

2

Active Trials

83

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractActive, not recruiting

GlaucomaRecruiting

CataractPhase 3

Active, not recruiting

GlaucomaPhase 3

Recruiting

Competition

Competitive Landscape

63 competitors in Cataract

#DrugCompanyPhaseTrials

Eylea

Avelox

Decadron

AAspen Global Incorporated

Bromday

BBausch Health Americas, Inc.

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Lovenox

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Voltaren

Cipro

Levaquin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Post-ApprovalRecruiting

Glaucoma

NCT07228221

Clinical

Trials by Indication[1]

Glaucoma1 trial

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Recruiting·JJonathon Myers·Phase 4·NCT07228221·20 enrolled

Cataract1 trial

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Active, not recruiting·GGlaukos Corporation·Phase 3·NCT06061718·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for iDose TR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iDose TR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iDose TR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Glaukos Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGlaukos Corporation

Related News